Amylyx Pharmaceuticals, Inc. Comprehensive Income
Amylyx Pharmaceuticals, Inc. (AMLX) reported Comprehensive Income of -$43.64 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-06
- Amylyx Pharmaceuticals, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$43.64M.
- Amylyx Pharmaceuticals, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$41.45M.
- Amylyx Pharmaceuticals, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$33.41M.
- Amylyx Pharmaceuticals, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$34.12M.
- Amylyx Pharmaceuticals, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$144.24M.
- Amylyx Pharmaceuticals, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$302.03M, a 709.50% decline from fiscal 2023.
- Amylyx Pharmaceuticals, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was $49.55M.
- Amylyx Pharmaceuticals, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$198.47M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$43.64M 10-Q · filed 2026-08-06 | -$85.09M 10-Q · filed 2026-08-06 | -$118.50M derived: sum of 3 quarters · filed 2026-08-06 | -$152.62M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$41.45M 10-Q · filed 2026-05-07 | -$74.86M derived: sum of 2 quarters · filed 2026-05-07 | -$108.98M derived: sum of 3 quarters · filed 2026-05-07 | -$149.87M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$33.41M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | -$67.53M derived: sum of 2 quarters · filed 2026-03-03 | -$108.42M derived: sum of 3 quarters · filed 2026-08-06 | -$144.24M 10-K · filed 2026-03-03 |
| 2025-09-30 | -$34.12M 10-Q · filed 2025-11-06 | -$75.01M derived: sum of 2 quarters · filed 2026-08-06 | -$110.83M 10-Q · filed 2025-11-06 | -$149.11M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$40.89M 10-Q · filed 2026-08-06 | -$76.71M 10-Q · filed 2026-08-06 | -$114.99M derived: sum of 3 quarters · filed 2026-08-06 | -$186.95M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$35.81M 10-Q · filed 2026-05-07 | -$74.09M derived: sum of 2 quarters · filed 2026-05-07 | -$146.06M derived: sum of 3 quarters · filed 2026-05-07 | -$218.78M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$38.28M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | -$110.25M derived: sum of 2 quarters · filed 2026-03-03 | -$182.97M derived: sum of 3 quarters · filed 2026-03-03 | -$302.03M 10-K · filed 2026-03-03 |
| 2024-09-30 | -$71.97M 10-Q · filed 2025-11-06 | -$144.69M derived: sum of 2 quarters · filed 2025-11-06 | -$263.75M 10-Q · filed 2025-11-06 | -$258.67M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$72.72M 10-Q · filed 2025-08-07 | -$191.79M 10-Q · filed 2025-08-07 | -$186.71M derived: sum of 3 quarters · filed 2025-08-07 | -$165.89M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$119.07M 10-Q · filed 2025-05-08 | -$113.99M derived: sum of 2 quarters · filed 2025-05-08 | -$93.17M derived: sum of 3 quarters · filed 2025-05-08 | -$71.20M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $5.08M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | $25.89M derived: sum of 2 quarters · filed 2025-03-04 | $47.87M derived: sum of 3 quarters · filed 2025-03-04 | $49.55M 10-K · filed 2025-03-04 |
| 2023-09-30 | $20.81M 10-Q · filed 2024-11-07 | $42.79M derived: sum of 2 quarters · filed 2024-11-07 | $44.48M 10-Q · filed 2024-11-07 | $2.41M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $21.98M 10-Q · filed 2024-08-08 | $23.66M 10-Q · filed 2024-08-08 | -$18.40M derived: sum of 3 quarters · filed 2024-08-08 | -$72.69M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $1.68M 10-Q · filed 2024-05-09 | -$40.38M derived: sum of 2 quarters · filed 2024-05-09 | -$94.67M derived: sum of 3 quarters · filed 2024-05-09 | -$148.78M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | -$42.06M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | -$96.35M derived: sum of 2 quarters · filed 2024-02-22 | -$150.46M derived: sum of 3 quarters · filed 2024-02-22 | -$198.47M 10-K · filed 2024-02-22 |
| 2022-09-30 | -$54.28M 10-Q · filed 2023-11-09 | -$108.40M derived: sum of 2 quarters · filed 2023-11-09 | -$156.41M 10-Q · filed 2023-11-09 | -$184.74M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | -$54.11M 10-Q · filed 2023-08-10 | -$102.12M 10-Q · filed 2023-08-10 | -$130.45M derived: sum of 3 quarters · filed 2024-02-22 | -$153.60M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | -$48.01M 10-Q · filed 2023-05-11 | -$76.34M derived: sum of 2 quarters · filed 2024-02-22 | -$99.48M derived: sum of 3 quarters · filed 2024-02-22 | -$121.41M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | -$28.33M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | -$51.48M derived: sum of 2 quarters · filed 2024-02-22 | -$73.40M derived: sum of 3 quarters · filed 2024-02-22 | -$87.92M 10-K · filed 2024-02-22 |
| 2021-09-30 | -$23.14M 10-Q · filed 2022-11-10 | -$45.06M derived: sum of 2 quarters · filed 2022-11-10 | -$59.59M 10-Q · filed 2022-11-10 | |
| 2021-06-30 | -$21.92M 10-Q · filed 2022-08-11 | -$36.45M 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | -$14.52M 10-Q · filed 2022-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |